Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial.

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial. European heart journal Lurz, P., Hahn, R. T., Kodali, S., Makkar, R., Sharma, R. P., Davidson, C. J., O'Neill, B. P., Yadav, P., Zahr, F., Chadderdon, S., Eleid, M. F., Szerlip, M., Smith, R., Whisenant, B., Garcia, S., Kister, T., Kipperman, R. M., Lim, S., Saxon, J., Kapadia, S., Hermiller, J., Mishell, J. M., Rassi, A., Herrmann, H. C., Szeto, W., Hausleiter, J., Babaliaros, V., Barker, C. M., Lindman, B. R., Latib, A., Muhammad, K., von Bardeleben, R. S., Summers, M., Chetcuti, S., Ailawadi, G., Russo, M., Rinaldi, M., Chehab, B. M., Nickenig, G., Stinis, C., Inglessis-Azuaje, I., Dhoble, A., Chhatriwalla, A. K., Petrossian, G., Shah, P., Staniloae, C., Williams, M., Nores, M., McCabe, J. M., Singh, G., Baldus, S., Rudolph, V., Barb, I., Klodell, C., Gray, W., Strote, J., Sannino, A., Grayburn, P., Mack, M. J., Leon, M. B., Thourani, V. H. 2025

Abstract

The TRISCEND II trial demonstrated superior clinical benefits for patients with =severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy versus medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity.The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, =severe TR and randomised 2:1 to TTVR (n=267) or control (n=133). In a post-hoc analysis, patients were stratified into severe TR (n=172) and massive/torrential TR (n=220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan-Meier estimates for all-cause mortality and heart failure (HF) hospitalisation assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board.One year after TTVR, TR was =mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe (1.64 [95% CI: 1.11, 2.43]) and massive/torrential (2.20 [1.55, 3.14]). At 18 months, TTVR patients had similar mortality to controls (rate difference: severe 0.2% [-11.6, 11.9], massive/torrential -5.8% [-17.6, 6.0], whereas HF hospitalisation rates favoured TTVR in the massive/torrential cohort (vs. control, severe 9.8% [-3.0, 22.7], massive/torrential -15.2% [-28.9, -1.5]).Patients with =severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.

View details for DOI 10.1093/eurheartj/ehaf676

View details for PubMedID 40878717